Curated News
By: NewsRamp Editorial Staff
October 27, 2026
GeoVax Secures $1M Loan, Overhauls Board to Advance Mpox Vaccine
TLDR
- GeoVax secured a $1 million revolving loan at 12% interest from Bowery Consulting, gaining working capital to advance its GEO-MVA vaccine program.
- The loan matures in 12 months, requires lender approval for advances, and led to three lender-nominated directors joining GeoVax's five-member board.
- GeoVax's financing supports development of vaccines for mpox, smallpox, and cancer, potentially improving global health preparedness and treatment options.
- As part of the loan agreement, five GeoVax directors resigned and three new directors were appointed, reshaping the board's composition.
Impact - Why it Matters
This news matters because the $1 million revolving loan provides GeoVax with critical working capital to advance its GEO-MVA mpox and smallpox vaccine program toward a Phase 3 trial, a key step in addressing global biodefense needs. The board restructuring, with lender-nominated directors, signals increased lender influence and may affect corporate governance. For investors, the financing reduces near-term liquidity risk but comes with a high 12% interest rate and potential dilution of control. For public health, progress on GEO-MVA could expand vaccine supply for orthopoxvirus threats. The changes also reflect the challenges small biotechs face in funding late-stage development.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, has secured an unsecured $1,000,000 revolving loan agreement with Bowery Consulting Group Inc., dated October 23, 2026. The facility allows advances up to $1,000,000, subject to lender approval, carries a 12% annual interest rate, and matures in 12 months. Concurrently, five directors—Randal Chase, Dean Kollintzas, Nicole Lemerond, Jayne Morgan, and John Spencer, Jr.—resigned, and Steven Brown, Tyler O’Brien, and Manpreet Uppal were appointed to the board, nominated by the lender. The board now comprises five directors, with O’Brien and Uppal joining the Audit Committee alongside Dr. Robert McNally. The company asserts that the new directors meet SEC and Nasdaq independence standards.
CEO David A. Dodd called the financing “an important achievement” that reinforces the balance sheet and provides working capital to support operations. He welcomed the new directors, citing their diverse experience and leadership as valuable for advancing the GEO-MVA clinical program, which targets mpox and smallpox and is on an expedited pathway toward a pivotal Phase 3 trial in late 2026. Dodd also thanked the departing board members for their contributions. GeoVax is also developing Gedeptin®, a gene-directed enzyme prodrug therapy for advanced head and neck cancer, and maintains a global intellectual property portfolio. Further details will be disclosed in a Form 8-K filing with the SEC. For more information, visit www.geovax.com.
The original release can be viewed on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, GeoVax Secures $1M Loan, Overhauls Board to Advance Mpox Vaccine
